Clinical data | ||
Age (min–max) (years) | 66 | (59–74) |
Male/female | 17/6 | (73.9%/26.1%) |
Liver cirrhosis | 0 | 0% |
Liver steatosis | 5 | 21.7% |
Previous chemotherapy | 17 | 73.9% |
Previous liver resection | 4 | 17.4% |
Primary tumour | ||
Colorectal cancer | 11 | 47.8% |
Cholangiocellular carcinoma | 4 | 13.0% |
Breast cancer | 3 | 17.3% |
Hepatocellular carcinoma | 1 | 4.3% |
Neuroendocrine tumour | 1 | 4.3% |
Renal cell carcinoma | 1 | 4.3% |
Oesophageal carcinoma | 1 | 4.3% |
Pancreatic ductal adenocarcinoma | 1 | 4.3% |
Mean (SD) 90Y dose to RLL (Gy/mL) | 45.7 | (7.5) |